Aorta stenosis (AS) keeps being increased in our country in association with social aging, and the number of aorta valve replacement for elder patients has also grown. However, there were an innegligible number of inoperable patients with AS because of comorbidity and/or high frailty. For these patients, transcatheter aorta valve replacement (TAVR) has been recently available in Japan and is conducted in the authorized institutes. However, as PARTNERIII trial have already finished, and its results will change the paradigm of AS treatment in the near future. For mitral regurgitation with high operative risks, in particular with severe ventricular dysfunction, the therapeutic strategy has not been established. MitraClip has been approved as a noninvasive procedure for patients with severe mitral regurgitation and high operative risks, and Clinical trial for approval of TMVR will start soon in Japan. Moreover, Amplazer for ASD have already been proved its clinical usefulness.
In this session, we would like to reconfirm points to be kept in mind to exert benefits through the transcatheter noninvasive therapy for Structure heart diseases and to discuss a plan for issues to be resolved.